Is the price fair?
What IBRX's price assumes
ImmunityBio, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 55.9× revenue.
55.9
Price / sales · no P/E: the last twelve months did not end in a profit
Details›
- EV / EBIToperating margin −152%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $7.71B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.